The journey towards clinical adoption of MALDI-MS-based imaging proteomics: from current challenges to future expectations

Piga I
First
;
2023-01-01

Abstract

Among the spatial omics techniques available, mass spectrometry imaging (MSI) represents one of the most promising owing to its capability to map the distribution of hundreds of peptides and proteins, as well as other classes of biomolecules, within a complex sample background in a multiplexed and relatively high-throughput manner. In particular, matrix-assisted laser desorption/ionisation (MALDI-MSI) has come to the fore and established itself as the most widely used technique in clinical research. However, the march of this technique towards clinical utility has been hindered by issues related to method reproducibility, appropriate biocomputational tools, and data storage. Notwithstanding these challenges, significant progress has been achieved in recent years regarding multiple facets of the technology and has rendered it more suitable for a possible clinical role. As such, there is now more robust and extensive evidence to suggest that the technology has the potential to support clinical decision-making processes under appropriate circumstances. In this review, we will discuss some of the recent developments that have facilitated this progress and outline some of the more promising clinical proteomics applications which have been developed with a clear goal towards implementation in mind.
2023
MALDI-MSI; clinical proteomics; machine learning; mass spectrometry; molecular pathology; proteomics; spatial omics.
Files in This Item:
File Size Format  
FEBS Letters - 2023 - Piga - The journey towards clinical adoption of MALDI‐MS‐based imaging proteomics from current (1).pdf

open access

Type: versione editoriale
Size 1.06 MB
Format Adobe PDF
1.06 MB Adobe PDF View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Questionnaire and social

Share on:
Impostazioni cookie